EXAGEN INC.(XGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

EXAGEN INC. (XGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XGN at 27.3/100 on a 32-signal composite quality model, placing it at rank #2,588 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (5.9) and balance sheet strength (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), EXAGEN INC. reports quarterly revenue of $19.9M, net income of $-3.2M, free cash flow of $3.4M. Top institutional holders of XGN by reported 13-F value include WEXFORD CAPITAL, NANO CAP NEW MILLENNIUM GROWTH FUND L P, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XGN trades on the Nasdaq exchange and files with the SEC under CIK 1274737. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXAGEN INC. directly from SEC EDGAR.